compass_positive_tagline-01.png
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression
June 28, 2021 07:00 ET | COMPASS Pathfinder Ltd.
London, UK, June 28, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
compass_positive_tagline-01.png
COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
June 23, 2021 07:00 ET | COMPASS Pathfinder Ltd.
Programme aims to support students from under-represented ethnic groups London, UK – 23 June 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to...
compass_positive_tagline-01.png
COMPASS Pathways plc to participate in JMP Securities and H.C. Wainwright investor conferences
June 08, 2021 07:00 ET | COMPASS Pathfinder Ltd.
LONDON, June 08, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
compass_positive_tagline-01.png
COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
June 03, 2021 09:27 ET | COMPASS Pathfinder Ltd.
LONDON, June 03, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
compass_positive_tagline-01.png
COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021
May 13, 2021 07:00 ET | COMPASS Pathfinder Ltd.
Highlights: New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder Two...
compass_positive_tagline-01.png
COMPASS Pathways plc to announce first quarter 2021 financial results on 13 May 2021
May 06, 2021 08:00 ET | COMPASS Pathfinder Ltd.
London, UK, May 06, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
compass_positive_tagline-01.png
COMPASS Pathways announces pricing of public offering
April 29, 2021 20:45 ET | COMPASS Pathfinder Ltd.
      London, UK, 30 April 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based...
compass_positive_tagline-01.png
COMPASS Pathways launches proposed public offering
April 27, 2021 17:22 ET | COMPASS Pathfinder Ltd.
London, UK, April 27, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
compass_positive_tagline-01.png
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
April 15, 2021 03:00 ET | COMPASS Pathfinder Ltd.
London, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
compass_positive_tagline-01.png
COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference
April 09, 2021 07:00 ET | COMPASS Pathfinder Ltd.
London, UK, April 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...